Skip to main content
SpringerLink
Log in

Alkalose, Albumin, Ammoniak und die hepatische Enzephalopathie

Alkalosis, albumin, ammonia and hepatic encephalopathy

  • Leserbriefe
  • Published:
Medizinische Klinik - Intensivmedizin und Notfallmedizin Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology 60(2):715–735

    Article  Google Scholar 

  2. Vince AJ, Burridge SM (1980) Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol 13(2):177–191

    Article  CAS  Google Scholar 

  3. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM (1974) Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut 15(12):999–1004

    Article  CAS  Google Scholar 

  4. Kiafar C, Gilani N (2008) Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 7(4):313–320

    Article  CAS  Google Scholar 

  5. Heinemann H (1960) Respiration and circulation in patients with portal cirrhosis of the liver. Circulation 22(1):154–159

    Article  CAS  Google Scholar 

  6. Lustik SJ, Chhibber AK, Kolano JW, Hilmi IA, Henson LC, Morris MC et al (1997) The hyperventilation of cirrhosis: progesterone and estradiol effects. Hepatology 25(1):55–58

    Article  CAS  Google Scholar 

  7. McAuliffe JJ, Lind LJ, Leith DE, Fencl V (1986) Hypoproteinemic alkalosis. Am J Med 81(1):86–90

    Article  CAS  Google Scholar 

  8. Funk G, Doberer D, Fuhrmann V, Holzinger U, Kitzberger R, Kneidinger N et al (2006) The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. J Hepatol 45(3):387–392

    Article  CAS  Google Scholar 

  9. Drolz A, Horvatits T, Roedl K, Rutter K, Brunner R, Zauner C et al (2018) Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Ann Intensive Care 8(1):1–12

    Article  CAS  Google Scholar 

  10. Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U et al (1998) Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 28(5):1215–1225

    Article  CAS  Google Scholar 

  11. Moroni F, Carpenedo R, Venturini I, Baraldi M, Zeneroli ML (1998) Oxindole in pathogenesis of hepatic encephalopathy. Lancet 351(9119:1861):78807–78803

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, OE 6810, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    A.-R. Kabbani, T. L. Tergast, M. P. Manns &  B. Maasoumy

Authors
  1. A.-R. Kabbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. L. Tergast
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. P. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Maasoumy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Maasoumy.

Ethics declarations

Interessenkonflikt

A.-R. Kabbani erklärt, dass er Verbindungen zu Merck/MSD (Reisekostenerstattung) hat. T.L. Tergast gibt an, dass kein Interessenkonflikt besteht. M.P. Manns erklärt, dass er Verbindungen (Principal Investigator/Studien/Vortrags-und Beraterhonorare) zu AbbVie, Bristol Myers Squibb, CureVac, Enyo Pharma, Falk Pharma, Janssen, Merck/MSD, Gilead Sciences, Medgenics, Novartis, Roche, PregLem, Gedeon Richter und Allergan hat; zudem werden Reisekosten von AbbVie, Bristol Myers Squibb, Janssen, Merck/MSD, Falk Pharma, Gilead Sciences, Novartis und Roche erstattet. B. Maasoumy hat Vortrags- und/oder Beraterhonorare von AbbVie, Bristol-Myers Squibb, Janssen, Merck/MSD, Abbott, Fujirebio, Roche; Studienunterstützung von Abbott, Fujirebio und Roche wie auch Reisekostenerstattungen von Gilead Science, Bristol-Myers Squibb, AbbVie, Merck/MSD und Janssen erhalten.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kabbani, AR., Tergast, T.L., Manns, M.P. et al. Alkalose, Albumin, Ammoniak und die hepatische Enzephalopathie. Med Klin Intensivmed Notfmed 116, 358–359 (2021). https://doi.org/10.1007/s00063-021-00812-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-021-00812-5

Search

Navigation